Key takeaway
Average daily acceleration was lower with cardio-metabolic disease in UK Biobank: 31 ± 12 mg in men with type 2 diabetes plus cardiovascular disease versus 42 ± 15 mg in healthy men. Disease was self-reported about 5 years before wrist monitoring, so the direction of cause is unclear.
Study design
Research article
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Cardio-metabolic disease and physical activity are closely connected, but large studies with objectively measured activity are scarce. The authors used the largest accelerometer cohort to date to ask whether disease status is associated with accelerometer measures after a 5-year follow-up.
Who and how
Cohort analysis of 106,053 UK Biobank participants who wore a wrist-worn GENEactiv monitor. Those with acceptable wear time (more than 3 days) were split into 4 cardio-metabolic disease groups based on self-reported disease status collected 5 ± 1 years earlier. Multiple linear regression models examined associations, controlling for confounders and stratified by gender. The title cites 52,556 participants; the abstract does not explain how this relates to the 106,053 who wore the monitor.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Average daily acceleration was lower with cardio-metabolic disease: in men, 'healthy' 42 ± 15 mg versus 'type 2 diabetes + cardiovascular disease' 31 ± 12 mg; in women, 44 ± 13 mg versus 31 ± 11 mg. This held across week and weekend days.
- 2Men and women with the worst cardio-metabolic disease did around half the daily moderate to vigorous physical activity of healthy individuals.
- 3They spent almost 7 h per day in 30-minute inactivity bouts.
- 4Significant associations between cardio-metabolic disease and accelerometer variables remained 5 years on after controlling for confounders.
Limits & uncertainty
- 1Disease was self-reported, and activity was measured once, so the direction of the association cannot be determined.
- 2UK Biobank volunteers tend to be a selected group, and the abstract does not describe the wear period, so results may not match the wider population.
- 3The abstract does not report confidence intervals for the adjusted associations or which confounders were included.
- 4This reading is based on the abstract only.
What to take from it
People with heart disease and diabetes together were much less active in daily life than healthy people, with long stretches of inactivity. That points to movement as an area worth discussing with a clinician, but this study cannot say whether more activity would improve disease.
Reading your own data
A wrist device's daily acceleration or active minutes, and long inactive stretches, are the same kind of data used in this study. Compare your own weeks using the same device and wear time; the absolute values depend on the device and its algorithm.
How to read this evidence
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Aim
Cardio-metabolic disease and physical activity are closely related but large-scale objective studies which measure physical activity are lacking. Using the largest accelerometer cohort to date, we aimed to investigate whether there is an association between disease status and accelerometer variables after a 5-year follow-up.
Methods
106,053 UK Biobank participants wore a wrist-worn GENEactiv monitor. Those with acceptable wear time (> 3 days) were split into 4 cardio-metabolic disease groups based on self-report disease status which was collected 5 ± 1 years prior. Multiple linear regression models were used to investigate associations, controlling for confounders and stratified for gender.
Results
Average daily acceleration was lower in men ('healthy'-42 ± 15 mg v 'Type 2 diabetes + cardiovascular disease (CVD)'-31 ± 12 mg) and women ('healthy'-44 ± 13 mg v 'Type 2 diabetes + CVD'-31 ± 11 mg) with cardio-metabolic disease and this was consistent across both week and weekend days. Men and women with the worst cardio-metabolic disease perform around half of moderate to vigorous physical activity on a daily basis compared to healthy individuals, and spend almost 7 h per day in 30 min inactivity bouts. Significant associations were seen between cardio-metabolic disease and accelerometer variables 5 years on when controlling for confounders.
Conclusion
In the largest accelerometer cohort to date, there are significant associations between cardio-metabolic disease and physical activity variables after 5 years of follow-up. Triaxial accelerometers provide enhanced measurement opportunities for measuring lifestyle behaviours in chronic disease.
Sources & attribution
Accelerometer-derived physical activity in those with cardio-metabolic disease compared to healthy adults: a UK Biobank study of 52,556 participants.
Cassidy S, Fuller H, Chau J, Catt M, Bauman A, Trenell MI.
Acta diabetologica · 2018-05-28
DOI: 10.1007/s00592-018-1161-8 ↗PubMed · 29808390 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Activity–stroke and heart attack curves differ by accelerometer processing method
Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.
Preventive Medicine
Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven
A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.
Forensic Science International
Activity trackers: about 1,800 more steps a day, but small effects on other outcomes
An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.
The Lancet Digital Health
Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages
In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.
Sleep

